Top Stories

Published on Thursday, September 12, 2019

The biological effects of double-dose alpha-1 antitrypsin augmentation therapy: A pilot clinical trial

The biological effects of double-dose alpha-1 antitrypsin augmentation therapy: A pilot clinical trial

The American Journal of Respiratory and Critical Care Medicine, of the American Thoracic Society (ATS), recently published an article about the outcomes of a clinical trial entitled: “Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation,” conducted by Michael Campos, MD, of the University of Miami.

Augmentation therapy with intravenous alpha-1 antitrypsin (AAT) is the only specific therapy for individuals with pulmonary disease from Alpha-1 Antitrypsin Deficiency (AATD). The recommended standard dose elevates AAT trough serum levels to around 50% of normal; however, outside of slowing emphysema progression, its effects in other clinical outcomes have not been rigorously proven.

The objectives of this study were to evaluate the biological effects of normalizing AAT trough levels with double-dose (DD) therapy in subjects with AATD already receiving standard-dose (SD) therapy.

The conclusions of the study found that subjects with AATD on SD augmentation therapy still exhibit inflammation, protease activity, and elastin degradation that can be further improved by normalizing AAT levels. Higher AAT dosing than currently recommended may lead to enhanced clinical benefits and should be explored further.

This study describes the effects of double-dose AAT therapy on several biological parameters associated with the development and progression of AATD-related chronic obstructive pulmonary disease (COPD). Overall, double-dose therapy was shown to restore serum AAT levels to greater than 25 μM and to further reduce circulating and airway levels of serine proteases, reduce elastin degradation in the lung, and diminish airway inflammation in subjects already receiving standard-dose therapy. Therefore, increasing AAT levels into the normal range may provide additional clinical benefits and have a more robust impact on clinical outcomes in subjects with AATD requiring augmentation therapy.

You can read the complete article by the American Journal of Respiratory and Critical Care Medicine, on the ATS Journals website, by clicking here.

This clinical trial is registered with (NCT 01669421).

Sources: American Journal of Respiratory and Critical Care Medicine,


Open Enrollment: A video series by NHC

Friday, November 15, 2019
The National Health Council (NHC) created a short video series to help users navigate the health insurance marketplace for Open Enrollment, which runs from Friday, November 1st through Sunday, December 15th, this year. Open Enrollment...

State and city proclamations raise Alpha-1 awareness during Alpha-1 Awareness Month

Monday, November 11, 2019
November has been marked as Alpha-1 Awareness Month to increase knowledge and spread awareness about Alpha-1 Antitrypsin Deficiency (Alpha-1) with several activities across the United States. You can read the official press release here. Many...

Powerful video raises awareness of COPD and the need for research funding

Monday, November 11, 2019
November is National Alpha-1 Awareness Month and is also National Chronic Obstructive Pulmonary Disease (COPD) Awareness Month, and a powerful new video has been released that raises awareness of the critical need for significantly increased COPD...

Alpha-1 Awareness Month 2019: Virtual Walks week 1 (recap)

Saturday, November 9, 2019
November represents Alpha-1 Awareness Month and the community has set the tone for the month in week one. Alphas, friends, and family joined together on November 2nd around the country in their purple shirts to spread awareness and raise funds for...

Grifols introduces AlphaID™, a free cheek swab to screen for Alpha-1, the most common genetic form of COPD

Friday, November 8, 2019
BARCELONA, Spain, Nov. 7, 2019 -- Grifols, a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, has now introduced AlphaID™, a new, simple cheek swab that can be used...

November is Alpha-1 Awareness Month

Friday, November 1, 2019
Miami, Nov. 1, 2019 – The month of November has been declared as Alpha-1 Awareness Month, by the Alpha-1 Foundation, to raise awareness about Alpha-1 Antitrypsin Deficiency (Alpha-1) throughout the United States. During November, several...

Mark Brantly, MD: Interim Scientific Director of the Alpha-1 Foundation

Wednesday, October 23, 2019
Mark Brantly, MD, has been named interim scientific director of the Alpha-1 Foundation, as Adam Wanner, MD, announced his resignation after 13 years of service to the Alpha-1 Foundation and the Alpha-1 community. Wanner served as scientific...

Jonathan Maidment completes a thru-hike of the Pacific Crest Trail raising awareness and funds for Alpha-1

Wednesday, October 16, 2019
October 16, 2019 – Hiking the Pacific Crest Trail (PCT) for the past seven months. Jonathan Maidment completes his journey to raise awareness and funds for Alpha-1 Antitrypsin Deficiency (Alpha-1). Holding up his Alpha Angels flag to honor...

Medicare: Open Enrollment for 2020

Monday, October 14, 2019
Medicare Open Enrollment begins on October 15, 2019 and ends on December 7, 2019. During this time, Medicare beneficiaries can compare coverage options like Original Medicare and Medicare Advantage and choose health and drug plans for...

Medicare Part D: Smoothing the out-of-pocket cap

Thursday, October 10, 2019
The Medicare Prescription drug benefit, or Part D, is an optional program from the Federal Government that helps older adults pay for their prescription drugs. Under Part D, the government and the individual share the cost of drugs up to a certain...

Escape to the Cape 2019: Team Alpha-1 at its best

Sunday, October 6, 2019
Even though the bike trek started with heavy hearts due to the very recent passing of two amazing Alpha volunteers, Susan Binnall and Alyce Yout, Team Alpha-1 pushed through and dedicated the ride to them: “Alyce & Sue This Rides for...

Open for comments: FDA proposes new required health warnings for cigarette packages

Tuesday, September 24, 2019
The U.S. Food and Drug Administration (FDA) issued a proposed rule to require new health warnings on cigarette packages and advertisements to promote greater public understanding of the negative health consequences of smoking. The agency...

Article Search

Enter keywords in text box and click Search button for results.